We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$4.8B
AUM Growth
+$87.7M
Cap. Flow
+$861M
Cap. Flow %
17.92%
Top 10 Hldgs %
41.63%
Holding
117
New
20
Increased
33
Reduced
18
Closed
25

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$187M
2
ISRG icon
Intuitive Surgical
ISRG
+$94.9M
3
HUM icon
Humana
HUM
+$83.2M
4
BIIB icon
Biogen
BIIB
+$79.4M
5
UNH icon
UnitedHealth
UNH
+$65.8M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$123M
2
ARNA
Arena Pharmaceuticals Inc
ARNA
+$113M
3
LLY icon
Eli Lilly
LLY
+$95.2M
4
HOLX
Hologic
HOLX
+$81.5M
5
SGEN
Seagen Inc. Common Stock
SGEN
+$79.1M

Sector Composition

Rank Sector Weight
1 Healthcare 91.22%
2 Financials 0.49%
3 Technology 0.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
101
Eli Lilly
LLY
$1.08T
– –
-344,800
Closed -$95.2M
MRUS
102
DELISTED
Merus
MRUS
– –
-103,000
Closed -$3.27M
PFE icon
103
Pfizer
PFE
$143B
– –
-2,090,000
Closed -$123M
RLMD icon
104
Relmada Therapeutics
RLMD
$555M
– –
-731,536
Closed -$16.5M
SHC icon
105
Sotera Health
SHC
$4.96B
– –
-2,960,000
Closed -$69.7M
STTK icon
106
Shattuck Labs
STTK
$642M
– –
-165,000
Closed -$1.4M
STVN icon
107
Stevanato
STVN
$5.56B
– –
-2,541,893
Closed -$57.1M
TCRT icon
108
Alaunos Therapeutics
TCRT
$4.69M
– –
-3,933
Closed -$643K
TIL icon
109
Instil Bio
TIL
$49.2M
– –
-20,407
Closed -$6.98M
TRDA icon
110
Entrada Therapeutics
TRDA
$254M
– –
-255,000
Closed -$4.37M
TRML
111
DELISTED
Tourmaline Bio
TRML
– –
-45,504
Closed -$6.96M
SLGCW
112
DELISTED
SomaLogic, Inc. Warrant
SLGCW
– –
-65,999
Closed -$220K
SLGC
113
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
– –
-330,000
Closed -$3.84M
EQRX
114
DELISTED
EQRx, Inc. Common Stock
EQRX
– –
-1,000,000
Closed -$6.82M
GBT
115
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-862,000
Closed -$25.2M
OCDX
116
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
– –
-1,790,000
Closed -$38.3M
ARNA
117
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-1,215,500
Closed -$113M
1 2 3 4
5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q1 2022 Portfolio in Review

As of Q1 2022, Avidity Partners Management held 117 positions worth $4.8B, up 1.9% from $4.71B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Avidity Partners Management deployed $861M of net new capital in Q1 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Merck: 2,370,000 shares worth $194M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 98% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $79.1M trimmed.

  • Avidity Partners Management's largest Q1 2022 buy was Merck: 2,370,000 shares worth $194M.
  • Avidity Partners Management added most to UnitedHealth in Q1 2022, an estimated $65.8M increase.
  • Avidity Partners Management's biggest Q1 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $79.1M.
  • Avidity Partners Management fully exited Pfizer in Q1 2022, selling an estimated $123M.
  • Avidity Partners Management's ten largest holdings make up 42% of its $4.8B portfolio in Q1 2022.
  • Avidity Partners Management opened 20 new positions and closed 25 in Q1 2022.
  • Avidity Partners Management's portfolio value rose 1.9% quarter-over-quarter to $4.8B.

Based on Avidity Partners Management's 13F filing for Q1 2022, filed 16 May 2022.